Exhibit 107
Calculation of Filing Fee Tables
S-8
(Form Type)
CytoMed Therapeutics Ltd
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered (1) | Proposed Maximum Offering Price Per Share (2) | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||||||||||||
| Equity | Ordinary Shares, no par value | Rule 457(c) and (h) | 1,279,117 | $ | 3.51 | $ | 4,489,700.67 | $ | 0.00015310 | $ | 687.37 | |||||||||||||
| Total Offering Amounts | $ | 687.37 | ||||||||||||||||||||||
| Total Fee Offsets | $ | 0 | ||||||||||||||||||||||
| Net Fee Due | $ | 687.37 | ||||||||||||||||||||||
| (1) | This Registration Statement on Form S-8 covers additional shares of Ordinary Shares, no par value, of CytoMed Therapeutics Ltd (“Registrant”) issuable pursuant to the 2023 Equity Incentive Plan (as amended and restated, the “2023 Equity Incentive Plan”) of the Registrant. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement is deemed to cover an indeterminate number of ordinary shares which may be offered and issued to prevent dilution resulting from share splits, share dividends or similar transactions as provided in the 2023 Equity Incentive Plan. |
| (2) | The proposed maximum offering price per share, which is estimated solely for the purposes of calculating the registration fee under Rule 457(h) and Rule 457(c) under the Securities Act, is based on US$3.51 per Ordinary Share, the average of the high and low prices for the Registrant’s Ordinary Share as quoted on the Nasdaq Capital Market on January 3, 2025. |
